Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid ...

Shares of several vaccine makers including Pfizer and Astrazeneca were down Friday morning following the nomination of Robert ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Along with possibly $150 million in milestone-based payments, BioNTech will pay $800 million in cash and a minor amount in ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...